tiprankstipranks
Trending News
More News >
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
US Market
Advertisement

Lexeo Therapeutics, Inc. (LXEO) Stock Forecast & Price Target

Compare
170 Followers
See the Price Targets and Ratings of:

LXEO Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Lexeo
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LXEO Stock 12 Month Forecast

Average Price Target

$14.60
▲(197.96% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Lexeo Therapeutics, Inc. in the last 3 months. The average price target is $14.60 with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 197.96% change from the last price of $4.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.61,5.793846153846154,6.977692307692308,8.161538461538463,9.345384615384617,10.529230769230772,11.713076923076924,12.896923076923077,14.080769230769231,15.264615384615386,16.44846153846154,17.632307692307695,18.81615384615385,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.61,5.378461538461538,6.146923076923077,6.915384615384616,7.6838461538461535,8.452307692307691,9.22076923076923,9.989230769230769,10.757692307692306,11.526153846153846,12.294615384615383,13.06307692307692,13.831538461538461,{"y":14.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.61,4.947692307692308,5.285384615384616,5.6230769230769235,5.960769230769231,6.298461538461539,6.636153846153846,6.973846153846154,7.311538461538461,7.649230769230769,7.986923076923077,8.324615384615385,8.662307692307692,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$14.60Lowest Price Target$9.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on LXEO
Leerink Partners
Leerink Partners
$10$9
Buy
83.67%
Upside
Reiterated
08/18/25
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Clover Health Investments (NASDAQ: CLOV) and Xilio Therapeutics (NASDAQ: XLO)Reiterate OP with our price target reduced from $10.00 to $9.00.
Chardan Capital Analyst forecast on LXEO
Chardan Capital
Chardan Capital
$20$15
Buy
206.12%
Upside
Reiterated
08/15/25
Lexeo Therapeutics price target lowered to $15 from $20 at ChardanLexeo Therapeutics price target lowered to $15 from $20 at Chardan
H.C. Wainwright Analyst forecast on LXEO
H.C. Wainwright
H.C. Wainwright
$15$9
Buy
83.67%
Upside
Reiterated
08/15/25
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments
RBC Capital Analyst forecast on LXEO
RBC Capital
RBC Capital
$20
Buy
308.16%
Upside
Reiterated
08/15/25
RBC Capital Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)
Oppenheimer Analyst forecast on LXEO
Oppenheimer
Oppenheimer
$20
Buy
308.16%
Upside
Initiated
07/31/25
Lexeo Therapeutics initiated with an Outperform at OppenheimerLexeo Therapeutics initiated with an Outperform at Oppenheimer
TR | OpenAI - 4o Analyst forecast on LXEO
TR | OpenAI - 4o
TR | OpenAI - 4o
Sell
Reiterated
04/20/25
AI Generated ArticleAI Generated Article
J.P. Morgan Analyst forecast on LXEO
J.P. Morgan
J.P. Morgan
Buy
Reiterated
04/10/25
Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating
Stifel Nicolaus Analyst forecast on LXEO
Stifel Nicolaus
Stifel Nicolaus
$21
Buy
328.57%
Upside
Reiterated
02/10/25
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from Stifel Nicolaus
Robert W. Baird Analyst forecast on LXEO
Robert W. Baird
Robert W. Baird
$28
Buy
471.43%
Upside
Reiterated
11/20/24
Lexeo Therapeutics' Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on LXEO
Leerink Partners
Leerink Partners
$10$9
Buy
83.67%
Upside
Reiterated
08/18/25
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Clover Health Investments (NASDAQ: CLOV) and Xilio Therapeutics (NASDAQ: XLO)Reiterate OP with our price target reduced from $10.00 to $9.00.
Chardan Capital Analyst forecast on LXEO
Chardan Capital
Chardan Capital
$20$15
Buy
206.12%
Upside
Reiterated
08/15/25
Lexeo Therapeutics price target lowered to $15 from $20 at ChardanLexeo Therapeutics price target lowered to $15 from $20 at Chardan
H.C. Wainwright Analyst forecast on LXEO
H.C. Wainwright
H.C. Wainwright
$15$9
Buy
83.67%
Upside
Reiterated
08/15/25
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments
RBC Capital Analyst forecast on LXEO
RBC Capital
RBC Capital
$20
Buy
308.16%
Upside
Reiterated
08/15/25
RBC Capital Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)
Oppenheimer Analyst forecast on LXEO
Oppenheimer
Oppenheimer
$20
Buy
308.16%
Upside
Initiated
07/31/25
Lexeo Therapeutics initiated with an Outperform at OppenheimerLexeo Therapeutics initiated with an Outperform at Oppenheimer
TR | OpenAI - 4o Analyst forecast on LXEO
TR | OpenAI - 4o
TR | OpenAI - 4o
Sell
Reiterated
04/20/25
AI Generated ArticleAI Generated Article
J.P. Morgan Analyst forecast on LXEO
J.P. Morgan
J.P. Morgan
Buy
Reiterated
04/10/25
Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating
Stifel Nicolaus Analyst forecast on LXEO
Stifel Nicolaus
Stifel Nicolaus
$21
Buy
328.57%
Upside
Reiterated
02/10/25
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from Stifel Nicolaus
Robert W. Baird Analyst forecast on LXEO
Robert W. Baird
Robert W. Baird
$28
Buy
471.43%
Upside
Reiterated
11/20/24
Lexeo Therapeutics' Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lexeo Therapeutics, Inc.

1 Month
xxx
Success Rate
5/9 ratings generated profit
56%
Average Return
+9.47%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +9.47% per trade.
3 Months
xxx
Success Rate
5/10 ratings generated profit
50%
Average Return
-0.79%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.79% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
4/9 ratings generated profit
44%
Average Return
-11.13%
reiterated a buy rating 10 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -11.13% per trade.
2 Years
xxx
Success Rate
4/9 ratings generated profit
44%
Average Return
-9.96%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of -9.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LXEO Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jul 25
Aug 25
Strong Buy
5
6
11
9
11
Buy
0
2
2
2
0
Hold
2
2
2
0
0
Sell
2
4
4
3
0
Strong Sell
0
0
0
0
0
total
9
14
19
14
11
In the current month, LXEO has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LXEO average Analyst price target in the past 3 months is 14.60.
Each month's total comprises the sum of three months' worth of ratings.

LXEO Financial Forecast

LXEO Earnings Forecast

Next quarter’s earnings estimate for LXEO is -$0.52 with a range of -$0.89 to -$0.32. The previous quarter’s EPS was -$0.60. LXEO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.04% of the time in the same period. In the last calendar year LXEO has Outperformed its overall industry.
Next quarter’s earnings estimate for LXEO is -$0.52 with a range of -$0.89 to -$0.32. The previous quarter’s EPS was -$0.60. LXEO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.04% of the time in the same period. In the last calendar year LXEO has Outperformed its overall industry.
No data currently available

LXEO Sales Forecast

Next quarter’s sales forecast for LXEO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LXEO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.24% of the time in the same period. In the last calendar year LXEO has Preformed in-line its overall industry.
Next quarter’s sales forecast for LXEO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LXEO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.24% of the time in the same period. In the last calendar year LXEO has Preformed in-line its overall industry.

LXEO Stock Forecast FAQ

What is LXEO’s average 12-month price target, according to analysts?
Based on analyst ratings, Lexeo Therapeutics, Inc.’s 12-month average price target is 14.60.
    What is LXEO’s upside potential, based on the analysts’ average price target?
    Lexeo Therapeutics, Inc. has 197.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LXEO a Buy, Sell or Hold?
          Lexeo Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Lexeo Therapeutics, Inc.’s price target?
            The average price target for Lexeo Therapeutics, Inc. is 14.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $9.00. The average price target represents 197.96% Increase from the current price of $4.9.
              What do analysts say about Lexeo Therapeutics, Inc.?
              Lexeo Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of LXEO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis